REGENXBIO Inc. (RGNX): Capital Expenditures
$2.41M
Year ended 2025-12-31
$2.99M
Trailing 12 months to 2026-06-30
-57.2%
3-year compound annual growth
-38.2%
5-year compound annual growth
+16.5%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.41M | -0.9% | 2026-03-05, From 2025-01-01 |
| 2024-12-31 | $2.44M | -75.5% | 2026-03-05, From 2024-01-01 |
| 2023-12-31 | $9.96M | -67.6% | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | $30.72M | -63.5% | 2025-03-13, From 2022-01-01 |
| 2021-12-31 | $84.17M | +213.3% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $26.87M | +129.3% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $11.72M | -11.7% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $13.28M | +85.4% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $7.16M | -12.1% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $8.15M | n/m | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $522.0K | n/a | 2018-03-06, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $2.41M | -0.9% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $7.67M | -87.7% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $886.0K | -81.1% |
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $14.95M | +67.1% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $4.70M | +17.9% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $145.0K | -73.8% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $0 | -100.0% |
| Agenus Inc (AGEN) | 2025-12-31 | $6.0K | -99.0% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $3.85M | -44.2% |
Compare RGNX, DNA, ADAPY, BEAM side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗